Personalizing Interventions Using Real-World Interactions

Status Completed

Clinical Trial Summary

Social functioning deficits are among the most disabling and difficult to treat aspects of schizophrenia. An essential component of social functioning is metacognition-a process that is profoundly disrupted in schizophrenia and represents the ability to reflect upon the mental states of oneself and others. To date, treatment efforts in schizophrenia have been hindered by barriers in accurately monitoring client's real-world social interactions. Recently, wearable technologies have evolved to provide therapists with innovative, ecologically-valid tools. The Electronically Activated Recorder is a wearable audio recorder that collects behavioral samples at pre-programmed intervals; it holds great promise as a method for yielding concrete, real-world examples of social interactions that can be used by therapists in session to enhance metacognition. Despite the immense costs of social functioning deficits, no previous studies have investigated whether functioning can be improved by integrating wearable audio recorders with psychosocial interventions. By enhancing therapy using a wearable recording device, this proposal's primary goal is to implement a novel intervention that targets metacognitive deficits to improve social functioning. The novel intervention will be tailored to individual clients-based on the content of recorded social interactions-in a way that is not possible using traditional psychotherapy. This will allow clients and therapists to step out of the therapy room by offering a window into how clients process material in real-world interactions. In this study, a randomized controlled trial will be conducted with two schizophrenia groups receiving six months of individualized: 1) Metacognition Reflection and Insight Therapy (MERIT) alone (Standard MERIT); and 2) Tailored MERIT using wearable audio recorders. In this study, our specific aims will test feasibility, effectiveness, and acceptability of Tailored MERIT.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Mental Disorders
Psychotic Disorders
Schizophrenia
Schizophrenia Spectrum and Other Psychotic Disorders
Social Interaction

Clinical Trial Details

NCT number	NCT04665401
Study type	Interventional
Source	Indiana University
Contact
Status	Completed
Phase	N/A
Start date	July 1, 2016
Completion date	March 15, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05321602` - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder	Phase 1
Recruiting	`NCT04298450` - ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention	N/A
Enrolling by invitation	`NCT03090490` - 10-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals	N/A
Completed	`NCT03323437` - Biomarkers of Conversion Risk and Treatment Response in Early-Stage Schizophrenia	Phase 4
Recruiting	`NCT06423651` - Benefits of Combining MCT With CR in the Recovery of Patients With Psychotic Spectrum Disorders	N/A
Completed	`NCT06040944` - Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
Recruiting	`NCT04452175` - Cigarette Consumption After switchinG to High or Low Nicotine strENght E-cigaretteS In Smokers With Schizophrenia	N/A
Completed	`NCT03501888` - Cognitive Behavior Therapy for Patients With Psychoses.	N/A
Completed	`NCT05601063` - Ascertaining Diagnosis Classification With Elicited Speech
Recruiting	`NCT05877716` - EPI-MINN: Targeting Cognition and Motivation - National	N/A
Completed	`NCT03955549` - Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial	Phase 3
Completed	`NCT03235908` - Copeptin in Outcome Prediction of an Acute Psychotic Episode
Recruiting	`NCT05622201` - A Randomized Controlled Trial With Rituximab for Psychotic Disorder in Adults	Phase 2
Recruiting	`NCT05491486` - Mindfulness, Empathy and the Oxytocinergic System in Persons With Schizophrenia	N/A
Completed	`NCT04916496` - Acceptance and Commitment Therapy-based Lifestyle Counselling Programme for Early Psychosis on Physical Activity	N/A
Recruiting	`NCT04104347` - Metacognitive Training and Insight in Schizophrenia	N/A
Recruiting	`NCT05664594` - State Representation in Early Psychosis - Project 4	N/A
Recruiting	`NCT05538832` - Remote State Representation in Early Psychosis	Early Phase 1
Completed	`NCT02220504` - 3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals	N/A
Recruiting	`NCT03919760` - Early Psychosis Intervention - Spreading Evidence-based Treatment

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.